Derick Todd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5844996/publications.pdf

Version: 2024-02-01

38	940	14	30
papers	citations	h-index	g-index
39	39	39	1830
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Use of Ablation Index-Guided Ablation Results in High Rates of Durable Pulmonary Vein Isolation and Freedom From Arrhythmia in Persistent Atrial Fibrillation Patients. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006576.	4.8	211
2	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, 2018, 39, 2942-2955.	2.2	181
3	Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace, 2016, 18, 151-155.	1.7	50
4	Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace, 2016, 18, 463-467.	1.7	49
5	Biatrial linear ablation in sustained nonpermanent AF: Results of the substrate modification with ablation and antiarrhythmic drugs in nonpermanent atrial fibrillation (SMAN-PAF) trial. Heart Rhythm, 2016, 13, 399-406.	0.7	47
6	Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 1596-1600.	1.7	46
7	Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). Europace, 2015, 17, 986-993.	1.7	38
8	Sameâ€day discharge in selected patients undergoing atrial fibrillation ablation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1448-1455.	1.2	38
9	Systematic reâ€evaluation of <i>SCN5A</i> variants associated with Brugada syndrome. Journal of Cardiovascular Electrophysiology, 2019, 30, 118-127.	1.7	36
10	Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. Europace, 2014, 16, 652-659.	1.7	33
11	Management of malfunctioning and recalled pacemaker and defibrillator leads: results of the European Heart Rhythm Association survey. Europace, 2014, 16, 1674-1678.	1.7	32
12	Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry. Catheterization and Cardiovascular Interventions, 2017, 89, 484-492.	1.7	31
13	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace, 2020, 22, 1026-1035.	1.7	26
14	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace, 2020, 22, 1337-1344.	1.7	21
15	Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1521-1523.	1.7	12
16	Standards for device implantation and follow-up: personnel, equipment, and facilities: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1236-1239.	1.7	11
17	Current implantable cardioverter-defibrillator programming in Europe: the results of the European Heart Rhythm Association survey. Europace, 2014, 16, 935-938.	1.7	10
18	Do cardiologists follow the European guidelines for cardiac pacing and resynchronization therapy? Results of the European Heart Rhythm Association survey. Europace, 2015, 17, 148-151.	1.7	10

#	Article	IF	CITATIONS
19	Complication rates following ventricular tachycardia ablation in ischaemic and non-ischaemic cardiomyopathies: a systematic review. Journal of Interventional Cardiac Electrophysiology, 2022, 63, 59-67.	1.3	9
20	Personnel, equipment, and facilities for electrophysiological and catheter ablation procedures in Europe: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1078-1082.	1.7	7
21	Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. Europace, 2014, 16, 698-702.	1.7	7
22	How are arrhythmias detected by implanted cardiac devices managed in Europe? Results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 1449-1453.	1.7	6
23	Ablation versus Anti-Arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent Atrial Fibrillation (AVATAR-AF): Design and rationale. American Heart Journal, 2019, 214, 36-45.	2.7	6
24	Natural progression of QRS duration in ICD-only patients. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 47-51.	1.3	5
25	Clinical predictors of informative genetic testing in hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 777-779.	1.8	5
26	How are European patients at risk of malignant arrhythmias or sudden cardiac death identified and informed about their risk profile: results of the European Heart Rhythm Association survey. Europace, 2015, 17, 994-998.	1.7	4
27	Safety of cryoballoon ablation for the treatment of atrial fibrillation: First European results from the cryo AF Global Registry. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 883-894.	1.2	3
28	Use of avatar virtual conferencing to co-ordinate cardiac multi-centre research. International Journal of Cardiology, 2014, 176, 1086-1088.	1.7	2
29	Demonstration of pulmonary vein exit block following pulmonary vein isolation: A novel use for adenosine. Journal of Cardiovascular Electrophysiology, 2018, 29, 1493-1499.	1.7	2
30	Retrograde aortic access during ventricular tachycardia ablation: Indications, techniques, and challenges. Journal of Cardiovascular Electrophysiology, 2019, 30, 2629-2639.	1.7	1
31	Management of paediatric arrhythmias in Europe: authors' reply. Europace, 2015, 17, 1879.2-1880.	1.7	0
32	89â€Radiofrequency Ablation of the Interventricular Septum to Treat Left Ventricular Outflow Tract Gradients in HOCM: Novel Use of Cartosound Technology to Guide Ablation. Heart, 2015, 101, A49-A50.	2.9	0
33	63â€Improving Safety and Clinical Outcomes for Atrial Fibrillation Ablation: Should Our Threshold for Referral and for Intervention Become Lower?. Heart, 2016, 102, A46-A46.	2.9	0
34	YOUNGER AGE, POSITIVE FAMILY HISTORY AND REVERSE CURVE MORPHOLOGY PREDICT INFORMATIVE RESULTS FROM GENE PANEL ANALYSIS FOR HYPERTROPHIC CARDIOMYOPATHY (HCM). Journal of the American College of Cardiology, 2017, 69, 835.	2.8	0
35	$20 \hat{a} \in$ Effect of shock therapy from implantable cardiac defibrillator on anxiety levels: a single-centre experience. , 2018, , .		0
36	27â€Has the time come for offering day-case atrial fibrillation ablation? patient and procedural characteristics indicative of early uptake. , 2018, , .		0

#	Article	lF	CITATIONS
37	134â€Clinical predictors of informative genetic testing in patients with Hypertrophic Cardiomyopathy (HCM)., 2019, , .		O
38	28â€Do the risks and benefits of thoracoscopic af ablation justify its endorsement in guidelines? a propensity matched study with catheter ablation. , 2018, , .		0